This Article


Creative Commons License
Except where otherwise noted, this work is licensed under Creative Commons Attribution-NonCommercial 4.0 International License.

Ovarian Cancer Staging by MDCT

1 Assistant professor of Tehran University of Medical Sciences, Tehran, Iran
*Corresponding author: Mahrooz Malek, Assistant professor of Tehran University of Medical Sciences, Tehran, Iran, E-mail:
Iranian Journal of Radiology. 2017 May; Special iss(5): e48366 , DOI: 10.5812/iranjradiol.48366
Article Type: Abstract; Received: Dec 21, 2016; Accepted: Feb 8, 2017; epub: Apr 13, 2017; ppub: May 2017


Ovarian cancer is the most lethal gynecological cancer and about 70% of the patients are advanced stagein the time of diagnosis. Decision about management (surgical debulking versus neoadjuant chemotherapy) in ovarian cancer patients is dependent on initial staging by abdominopelvic MDCT or MRI, so, Radiologist expertise on ovarian cancer staging is very important. Involvement of mesenteric root, peritoneal implante larger than 2 cm, lymphadenopathy superior to renal hilum and implants near hepatic veins are criteria for nonresectability of ovarian cancer and radiologist must be familiar and expert on the imaging protocol and findings on MDCT for ovarian cancer staging.

This is an abstract presented in the 33rd Iranian congress of radiology (ICR) and the 15th congress of Iranian radiographic science association (IRSA).